ALZCUR — AlzeCure Pharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK193.06m
- SEK145.28m
Annual income statement for AlzeCure Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | PRESS | PRESS |
| Standards: | IFRS | IFRS | IFRS | — | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 77.9 | 56.4 | 38.3 | 36 | 47.9 |
| Operating Profit | -77.9 | -56.4 | -38.3 | -36 | -47.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -77.8 | -56.2 | -37.2 | -35.4 | -47.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -77.8 | -56.2 | -37.2 | -35.3 | -47.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -77.8 | -56.2 | -37.2 | -35.3 | -47.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -77.8 | -56.2 | -37.2 | -35.3 | -47.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.77 | -1.06 | -0.536 | -0.458 | -0.474 |
| Dividends per Share |